Literature DB >> 24711380

Erbin is a negative modulator of cardiac hypertrophy.

Inbal Rachmin1, Sagi Tshori, Yoav Smith, Amit Oppenheim, Sylvie Marchetto, Gillian Kay, Roger S-Y Foo, Noa Dagan, Eliahu Golomb, Dan Gilon, Jean-Paul Borg, Ehud Razin.   

Abstract

ErbB2 interacting protein (Erbin) is a widely expressed protein and participates in inhibition of several intracellular signaling pathways. Its mRNA has been found to be present in relatively high levels in the heart. However, its physiological role in the heart has not been explored. In the present work, we elucidated the role of Erbin in cardiac hypertrophy. Cardiac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction. The level of Erbin was significantly decreased in both models. Erbin(-/-) mice rapidly develop decompensated cardiac hypertrophy, and following severe pressure overload all Erbin(-/-) mice died from heart failure. Down-regulation of Erbin expression was also observed in biopsies derived from human failing hearts. It is known that Erbin inhibits Ras-mediated activation of the extracellular signal-regulated kinase (ERK) by binding to Soc-2 suppressor of clear homolog (Shoc2). Our data clearly show that ERK phosphorylation is enhanced in the heart tissues of Erbin(-/-) mice. Furthermore, we clearly demonstrate here that Erbin associates with Shoc2 in both whole hearts and in cardiomyocytes, and that in the absence of Erbin, Raf is phosphorylated and binds Shoc2, resulting in ERK phosphorylation. In conclusion, Erbin is an inhibitor of pathological cardiac hypertrophy, and this inhibition is mediated, at least in part, by modulating ERK signaling.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24711380      PMCID: PMC4000781          DOI: 10.1073/pnas.1320350111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Erbin suppresses the MAP kinase pathway.

Authors:  Yang Z Huang; Mengwei Zang; Wen C Xiong; Zhijun Luo; Lin Mei
Journal:  J Biol Chem       Date:  2002-10-11       Impact factor: 5.157

2.  Erbin is a protein concentrated at postsynaptic membranes that interacts with PSD-95.

Authors:  Y Z Huang; Q Wang; W C Xiong; L Mei
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

3.  The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development.

Authors:  Richard Chan; William R Hardy; Michael A Laing; Sarah E Hardy; William J Muller
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

4.  The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.

Authors:  O F Bueno; L J De Windt; K M Tymitz; S A Witt; T R Kimball; R Klevitsky; T E Hewett; S P Jones; D J Lefer; C F Peng; R N Kitsis; J D Molkentin
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

5.  ErbB2 is essential in the prevention of dilated cardiomyopathy.

Authors:  Steven A Crone; You-Yang Zhao; Lian Fan; Yusu Gu; Susumu Minamisawa; Yang Liu; Kirk L Peterson; Ju Chen; Ronald Kahn; Gianluigi Condorelli; John Ross; Kenneth R Chien; Kuo-Fee Lee
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

6.  NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK.

Authors:  R R Baliga; D R Pimental; Y Y Zhao; W W Simmons; M A Marchionni; D B Sawyer; R A Kelly
Journal:  Am J Physiol       Date:  1999-11

7.  Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Authors:  Benjamin J Wilkins; Yan-Shan Dai; Orlando F Bueno; Stephanie A Parsons; Jian Xu; David M Plank; Fred Jones; Thomas R Kimball; Jeffery D Molkentin
Journal:  Circ Res       Date:  2003-12-01       Impact factor: 17.367

Review 8.  Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy.

Authors:  Christopher G Proud
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

Review 9.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

10.  β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes.

Authors:  Ming Shi; Mingzhen Zhao; Meiru Hu; Dan Liu; Hong Cao; Lu Qian; Zhengyan Yang; Yabin Hu; Ming Yu; Shuo Yang; Yuanfang Ma; Ning Guo
Journal:  Int J Cardiol       Date:  2012-05-06       Impact factor: 4.164

View more
  18 in total

Review 1.  The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease.

Authors:  HyeIn Jang; Payton Stevens; Tianyan Gao; Emilia Galperin
Journal:  FEBS J       Date:  2020-07-06       Impact factor: 5.542

Review 2.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

3.  Regeneration of Functional Adrenal Tissue Following Bilateral Adrenalectomy.

Authors:  Neta Gotlieb; Ely Albaz; Lee Shaashua; Liat Sorski; Pini Matzner; Ella Rosenne; Benjamin Amram; Amit Benbenishty; Eli Golomb; Shamgar Ben-Eliyahu
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

4.  FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy.

Authors:  Inbal Rachmin; Eden Amsalem; Eliahu Golomb; Ronen Beeri; Dan Gilon; Pengfei Fang; Hovav Nechushtan; Gillian Kay; Min Guo; Peter Li Yiqing; Roger S-Y Foo; David E Fisher; Ehud Razin; Sagi Tshori
Journal:  Int J Cardiol       Date:  2015-05-20       Impact factor: 4.164

5.  Star-PAP controlled alternative polyadenylation coupled poly(A) tail length regulates protein expression in hypertrophic heart.

Authors:  A P Sudheesh; Nimmy Mohan; Nimmy Francis; Rakesh S Laishram; Richard A Anderson
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

6.  ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction.

Authors:  Marie-Claude Perry; Catherine R Dufour; Lillian J Eichner; David W K Tsang; Geneviève Deblois; William J Muller; Vincent Giguère
Journal:  Mol Cell Biol       Date:  2014-09-22       Impact factor: 4.272

7.  Erbin Suppresses KSR1-Mediated RAS/RAF Signaling and Tumorigenesis in Colorectal Cancer.

Authors:  Payton D Stevens; Yang-An Wen; Xiaopeng Xiong; Yekaterina Y Zaytseva; Austin T Li; Chi Wang; Ashley T Stevens; Trevor N Farmer; Tong Gan; Heidi L Weiss; Masaki Inagaki; Sylvie Marchetto; Jean-Paul Borg; Tianyan Gao
Journal:  Cancer Res       Date:  2018-07-06       Impact factor: 13.312

Review 8.  Scaffold Proteins Regulating Extracellular Regulated Kinase Function in Cardiac Hypertrophy and Disease.

Authors:  Yan Liang; Farah Sheikh
Journal:  Front Pharmacol       Date:  2016-02-29       Impact factor: 5.810

9.  The function of Shoc2: A scaffold and beyond.

Authors:  Eun Ryoung Jang; Emilia Galperin
Journal:  Commun Integr Biol       Date:  2016-05-18

10.  Identification of the Mtus1 Splice Variant as a Novel Inhibitory Factor Against Cardiac Hypertrophy.

Authors:  Shin Ito; Masanori Asakura; Yulin Liao; Kyung-Duk Min; Ayako Takahashi; Kazuhiro Shindo; Satoru Yamazaki; Osamu Tsukamoto; Hiroshi Asanuma; Masaki Mogi; Masatsugu Horiuchi; Yoshihiro Asano; Shoji Sanada; Tetsuo Minamino; Seiji Takashima; Naoki Mochizuki; Masafumi Kitakaze
Journal:  J Am Heart Assoc       Date:  2016-07-06       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.